During the last session, ProQR Therapeutics N.V (NASDAQ:PRQR)’s traded shares were 0.32 million, with the beta value of the company hitting 0.19. At the end of the trading day, the stock’s price was $1.40, reflecting an intraday loss of -2.10% or -$0.03. The 52-week high for the PRQR share is $4.62, that puts it down -230.0 from that peak though still a striking -2.14% loss since the share price plummeted to a 52-week low of $1.43. The company’s market capitalization is $147.29M, and the average intraday trading volume over the past 10 days was 0.91 million shares, and the average trade volume was 456.60K shares over the past three months.
ProQR Therapeutics N.V (PRQR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. PRQR has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.16.
ProQR Therapeutics N.V (NASDAQ:PRQR) trade information
ProQR Therapeutics N.V (PRQR) registered a -2.10% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.10% in intraday trading to $1.40, hitting a weekly high. The stock’s 5-day price performance is -15.15%, and it has moved by -40.17% in 30 days. Based on these gigs, the overall price performance for the year is -41.67%. The short interest in ProQR Therapeutics N.V (NASDAQ:PRQR) is 1.02 million shares and it means that shorts have 2.51 day(s) to cover.
The consensus price target of analysts on Wall Street is $3.75, which implies an increase of 62.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $5 respectively. As a result, PRQR is trading at a discount of -257.14% off the target high and -42.86% off the low.
ProQR Therapeutics N.V (PRQR) estimates and forecasts
In the rating firms’ projections, revenue will decrease -22.07% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 4.9M as predicted by 7 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to 4.9M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 5.02M and 7.05M respectively. In this case, analysts expect current quarter sales to shrink by -2.44% and then drop by -30.51% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 25.70%. While earnings are projected to return -30.63% in 2025, the next five years will return -17.81% per annum.
PRQR Dividends
ProQR Therapeutics N.V is due to release its next quarterly earnings on 2025-Mar-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
ProQR Therapeutics N.V (NASDAQ:PRQR)’s Major holders
ProQR Therapeutics N.V insiders own 18.06% of total outstanding shares while institutional holders control 53.87%, with the float percentage being 65.75%. PRIVIUM FUND MANAGEMENT B.V. is the largest shareholder of the company, while 84.0 institutions own stock in it. As of 2024-06-30, the company held over 5.58 million shares (or 6.8336% of all shares), a total value of $9.21 million in shares.
The next largest institutional holding, with 3.63 million shares, is of ADAGE CAPITAL PARTNERS GP, L.L.C.’s that is approximately 4.4394% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $6.02 million.
Also, the Mutual Funds coming in first place with the largest holdings of ProQR Therapeutics N.V (PRQR) shares are Delaware Group Equity Funds IV-Macquarie Healthcare Fund and Meridian Fund Inc-Meridian Small Cap Growth Fund . Data provided on Dec 31, 2024 indicates that Delaware Group Equity Funds IV-Macquarie Healthcare Fund owns about 620.0 shares. This amounts to just over 0.59 percent of the company’s overall shares, with a $0.87 million market value. The same data shows that the other fund manager holds slightly less at 520.25, or about 0.49% of the stock, which is worth about $0.73 million.
